Mucosolvan Junior (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mucosolvan Junior, is a mucolytic presented as an oral suspension (strength not specified) for oral use. It helps relieve cough with thick mucus in children and supports clearance of bronchial secretions during respiratory infections.

GNH USA supplies Mucosolvan Junior as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mucosolvan Junior, a mucolytic, is indicated for conditions involving thick bronchial secretions.

- Cough with thick mucus: loosens and facilitates removal of viscous sputum. - Bronchitis: promotes expectoration and may shorten cough duration. - Respiratory tract infections: aids mucus clearance to improve airway patency.

Mucosolvan Junior is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea - Diarrhoea - Stomach discomfort or abdominal pain - Skin rash or mild itching - Taste disturbance - Headache

Serious or Rare Side Effects: - Allergic reactions such as anaphylaxis or angio‑edema - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hepatic enzyme elevation or liver dysfunction - Hematologic abnormalities (e.g., eosinophilia) - Acute bronchospasm in susceptible individuals

Before using Mucosolvan Junior, consider the following safety measures.

- Age limitation: not recommended for children under 2 years unless specifically advised by a healthcare professional. - Renal impairment: use with caution and monitor renal function. - Asthma or reactive airway disease: observe for possible bronchospasm. - Pregnancy: consult a physician; safety data are limited. - Concomitant medications: review all current drugs for potential interactions. - Store at ambient temperature below 25 °C: keep in the original pack, protect from moisture and direct sunlight.

Mucosolvan Junior may interact with other medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Anticholinergic agents: may diminish the mucolytic effect. - Cytotoxic chemotherapy: potential increase in pulmonary toxicity. - MAO inhibitors: risk of heightened adverse reactions.

Moderate Interactions (Monitor Closely): - Beta‑2 agonists: possible synergistic bronchodilation. - Macrolide antibiotics (e.g., erythromycin): may raise ambroxol plasma levels. - Alcohol: can exacerbate gastrointestinal irritation. - Other mucolytics or expectorants: may lead to excessive mucus thinning.